| 301 |
12882909 | Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. | 2003 Aug |
2 |
| 302 |
12917943 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. | 2003 |
1 |
| 303 |
12924536 | Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. | 2003 Jun |
3 |
| 304 |
12940867 | Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. | 2003 Sep |
3 |
| 305 |
12954157 | Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. | 2003 Sep-Oct |
1 |
| 306 |
12957323 | Insulin resistance, inflammation, and the prediabetic state. | 2003 Aug 18 |
1 |
| 307 |
14512888 | Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. | 2003 Oct |
2 |
| 308 |
14520628 | Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. | 2003 Oct |
3 |
| 309 |
14553866 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. | 2003 |
1 |
| 310 |
14624133 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. | 2003 Dec |
1 |
| 311 |
14642684 | The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. | 2003 Nov 19 |
2 |
| 312 |
14668701 | The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. | 2003 |
1 |
| 313 |
14669724 | Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Metabolic update: better defining lipodystrophy and treating insulin resistance. | 2003 Sep |
1 |
| 314 |
14671216 | Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. | 2003 Dec |
4 |
| 315 |
14679177 | Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. | 2003 Dec |
1 |
| 316 |
11872682 | The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. | 2002 Mar |
2 |
| 317 |
11881246 | [A case report. Rosiglitazone treatment was highly effective yet had to be terminated]. | 2002 Jan 31 |
1 |
| 318 |
11903029 | Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. | 2002 Mar 20 |
3 |
| 319 |
11978647 | Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. | 2002 May |
1 |
| 320 |
12099960 | Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. | 2002 Jul |
1 |
| 321 |
12133398 | [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome]. | 2002 May |
3 |
| 322 |
12149047 | Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. | 2002 |
3 |
| 323 |
12173915 | Thiazolidinedione therapy in a patient with diabetes after cardiac transplantation. | 2002 Jul-Aug |
3 |
| 324 |
12376581 | Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. | 2002 Oct |
6 |
| 325 |
12453903 | Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. | 2002 Dec |
4 |
| 326 |
12466369 | Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. | 2002 Dec |
1 |
| 327 |
12469695 | Rosiglitazone and pioglitazone: new preparations. Two new oral antidiabetics both poorly assessed. | 2002 Dec |
1 |
| 328 |
15832493 | Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. | 2002 |
3 |
| 329 |
11160777 | New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. | 2001 |
2 |
| 330 |
11232013 | Rosiglitazone monotherapy is effective in patients with type 2 diabetes. | 2001 Jan |
2 |
| 331 |
11336599 | Rosiglitazone. | 2001 Mar |
3 |
| 332 |
11380072 | The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes. | 2001 May |
2 |
| 333 |
11422732 | Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. | 2001 Jul |
1 |
| 334 |
11423507 | A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. | 2001 Jul |
2 |
| 335 |
11460577 | Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. | 2001 |
1 |
| 336 |
11560198 | A review of rosiglitazone in type 2 diabetes mellitus. | 2001 Sep |
3 |
| 337 |
11560925 | Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. | 2001 Dec 7 |
2 |
| 338 |
11561143 | Insulin action in the vasculature: physiology and pathophysiology. | 2001 Sep-Oct |
2 |
| 339 |
11579205 | Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. | 2001 Oct |
2 |
| 340 |
11704136 | Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. | 2001 Nov |
3 |
| 341 |
11712407 | [Rosiglitazone(BRL-49653)]. | 2001 Nov |
4 |
| 342 |
11715668 | [News in oral antidiabetic therapy]. | 2001 Sep |
2 |
| 343 |
11793023 | Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. | 2001 Dec |
2 |
| 344 |
11887975 | Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. | 2001 Nov |
6 |
| 345 |
10691158 | Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. | 2000 Jan |
1 |
| 346 |
10707565 | [Rosiglitazone (BRL-49653)]. | 2000 Feb |
3 |
| 347 |
10768088 | Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. | 2000 Mar |
3 |
| 348 |
10857389 | Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control. | 2000 |
1 |
| 349 |
10859151 | Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. | 2000 Jul |
2 |
| 350 |
10872292 | [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs]. | 2000 May 25 |
1 |